ACT : Analysis & Opinions

  1. Pharmacyclics Reveals FDA Action Date for Imbruvica sNDA - Analyst ...

    December 23, 2014
    Pharmacyclics, Inc. (PCYC) announced that the FDA is expected to render a final opinion on the supplemental New Drug Application ...
  2. Bristol-Myers Oncology Drug Opdivo Receives FDA Approval - Analyst ...

    December 23, 2014
    Bristol-Myers Squibb Company announced that the FDA has cleared its intravenous human programmed death receptor-1 blocking ...
  3. Actavis' Antibiotic a Step Closer to EU Nod, CHMP Positive - ...

    December 22, 2014
    Actavis' (ACT) antibiotic, Xydalba, which is already marketed in the U.S. under the trade name Dalvance, is a step closer ...
  4. Cubist's Antibiotic Zerbaxa Wins FDA Nod for cUTI and cIAI - ...

    December 22, 2014
    Cubist's (CBST) antibiotic, Zerbaxa gained FDA approval for the treatment of adults with complicated urinary tract infections ...
  5. Actavis plc (ACT): New Analyst Report from Zacks Equity Research ...

    December 22, 2014
    Actavis' third quarter 2014 EPS came in at $3.19, beating the Zacks Consensus Estimate of $3.12 per share and increasing ...
  6. Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst ...

    December 18, 2014
    Emergent BioSolutions Inc. announced that it has entered into an agreement with Evolva Holding for acquiring the latter's ...
  7. Cyclacel Falls on Poor Acute Myeloid Leukemia Drug Data - Analyst ...

    December 17, 2014
    In the SEAMLESS study on sapacitabine, the DSMB found that the planned futility boundary has been crossed.
  8. Alexion Announces New Share Repurchase Program of $500M - Analyst ...

    December 16, 2014
    Alexion Pharmaceuticals, Inc. (ALXN) announced that a new share repurchase program of up to $500 million have been authorized ...
  9. Actavis to Appeal Ruling Regarding Namenda IR Sales - Analyst ...

    December 16, 2014
    Actavis plc (ACT) announced its decision to file an emergency appeal for an immediate overturn of the lower court ruling ...
  10. ChemoCentryx Up on Positive Diabetic Nephropathy Data - Analyst ...

    December 15, 2014
    ChemoCentryx, Inc., announced positive top-line 52-week data from its phase II study on its candidate CCX140 for diabetic ...
  11. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  12. All Quiet On The Market Front: Dow, S&P 500, Nasdaq Virtually ...

    November 12, 2014
    U.S. stocks were little changed on Wednesday in another quiet trading session due to a lack of catalysts to move stocks. ...
  13. Wall Street's Latest Tax Craze... And How To Profit

    September 18, 2014
    A couple weeks ago in StreetAuthority Daily, we talked about some of Corporate America's latest financial engineering ...
  14. Capitalize On Wall Street's Latest Tax Craze

    September 18, 2014
    A couple weeks ago in StreetAuthority Daily, we talked about some of Corporate America's latest financial engineering ...
  15. Tight Consolidation Breakouts To Watch

    September 4, 2014
    Keep an eye on these four stocks for near-term consolidation breakouts.
  16. Is This The Best Health Care Stock To Own Right Now?

    July 24, 2014
    Although investing is about making money, I've noticed that losses are what really stick out in people's minds. If ...
  17. The Best Health Care Stock To Own Right Now

    July 24, 2014
    Although investing is about making money, I've noticed that losses are what really stick out in people's minds. If ...
  18. Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry ...

    July 24, 2014
    Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
  19. 3 Absolute Must-Own Dividend Aristocrats

    July 22, 2014
    What's your dividend style? Do you seek out the highest dividend yields, or stocks with the most impressive track record ...
  20. These four stocks just broke out of triangle chart patterns and provide upside targets as well as defined stop levels.

    Four Upside Triangle Chart Pattern Breakouts

    May 28, 2014
    These four stocks just broke out of triangle chart patterns and provide upside targets as well as defined stop levels.
  21. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  22. Since Warren Buffett's moves are so widely followed, we’ve chosen to take the path less traveled by looking at ten influential managers that don’t quite get the same media attention.

    Ten Money Managers Worth Following

    December 23, 2013
    Generally speaking, most retail investors along with the media outlets tend to closely follow the moves of well-known investors ...
  23. These Are America's Fastest-Growing Blue Chips

    December 4, 2013
    As company executives sit down to establish their 2014 strategies, they're faced with a sobering prospect: The U.S. economy ...
  24. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  25. Big Pharma Faces 'Pay For Delay' Lawsuits

    June 21, 2013
    Unless you follow the pharmaceutical and biotech sectors, it’s likely that you’ve never heard of pay to delay. Instead of ...
  26. A Good Deal For Actavis, But Warner Chilcott Goes A Little Cheap

    May 21, 2013
    Actavis gets a very useful asset, while Warner Chilcott shareholders get a decent exit.
  27. Teva Still Too Cheap, But Still Too Uncertain

    May 3, 2013
    Teva's present-day momentum is weak, but the value could appeal to patient long-term investors.
Trading Center